hyperplasia.On February 22, 2005, the US FDA doxazosin mesylate 4 mg a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure doxazosin mesylate 4 mg benign doxazosin mesylate 4 mg hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is Cardura®.

65%Protein binding 98%Metabolism HepaticHalf life 22 hoursExcretion ?Therapeutic considerationsPregnancy cat. ?Legal status ? Prescription onlyRoutes oralDoxazosin doxazosin mesylate 4 mg doxazosin mesylate 4 mg quinazoline compound sold by Pfizer under the brand names Cardura® and Carduran® , is doxazosin mesylate 4 mg alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure doxazosin mesylate 4 mg benign prostatic hyperplasia.On February 22, 2005, the US FDA approved doxazosin mesylate 4 mg sustained release form of doxazosin mesylate 4 mg to doxazosin mesylate 4 mg marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On doxazosin mesylate 4 mg 22, 2005, the US FDA approved a sustained release form of doxazosin.

autonomic nervous system. The primary effect of this blockage doxazosin mesylate 4 mg relaxed vascular smooth muscle tone (vasodilation), which.